The success of immunotherapeutic approaches targeting glioblastoma multiforme (GBM) demands a robust antiglioma T-cell cytotoxic and memory response. Recent evidence suggests that rapamycin regulates T-cell differentiation. Herein, we tested whether administration of rapamycin could enhance the efficacy of immunotherapy utilizing Fms-like tyrosine kinase 3 ligand (Ad-Flt3L) and thymidine kinase/ganciclovir (Ad-TK/GCV). Using the refractory rat RG2 glioma model, we demonstrate that administration of rapamycin with Ad-Flt3L þ Ad-TK/GCV immunotherapy enhanced the cytotoxic activity of antitumor CD8 þ T cells. Rats treated with rapamycin þ Ad-Flt3L þ Ad-TK/GCV exhibited massive reduction in the tumor volume and extended survival. Rapamycin administration also prolonged the survival of Ad-Flt3L þ Ad-TK/GCV-treated GL26 tumor-bearing mice, associated with an increase in the frequency of tumor-specific and IFNg þ CD8 þ T cells. More importantly, rapamycin administration, even for a short interval, elicited a potent long-lasting central memory CD8 þ T-cell response. The enhanced memory response translated to an increased frequency of tumor-specific CD8 þ T cells within the tumor and IFNg release, providing the mice with long-term survival advantage in response to tumor rechallenge. Our data, therefore, point to rapamycin as an attractive adjuvant to be used in combination with immunotherapy in a phase I clinical trial for GBM. Mol Cancer Ther; 13(12); 1-13. Ó2014 AACR.
Introduction
Malignant cancers of the central nervous system, i.e., glioblastoma multiforme grade 4 (GBM), are characterized by a high degree of immune suppression, mediated by high levels of TGFb and/or IL10, which leads to an increase in T regulatory (Treg) cells, lack of lymphatic drainage, presence of the blood-brain barrier, and a paucity of antigen-presenting cells such as dendritic cells (DC) within the brain parenchyma (1) (2) (3) . Taking into account these features, we developed a gene therapy-mediated immune-stimulatory approach for GBM, which relies on the expression of thymidine kinase (TK) that phosphorylates and activates the prodrug ganciclovir (GCV) inducing the death of actively proliferating tumor cells with the concomitant release of the endogenous TLR ligand, Highmobility group B1 protein (HMGB1); and Fms-like tyrosine kinase 3 ligand (Flt3L) that increases the recruitment of DCs to the tumor microenvironment (4) (5) (6) (7) . HMGB1 induces the maturation of DCs with the upregulation of costimulatory ligands and MHC II molecules and release of inflammatory cytokines such as IL12 and IFNg, polarizing them toward an activated phenotype (8) . The activated DCs subsequently prime antitumor T-cell responses in the draining lymph nodes (dLN). Cytotoxic CD8 þ T cells are well recognized to mediate effective antitumor immunity (9) . In addition, T H 1 skewed CD4 þ T cells also play an important role in enhancing the CD8 þ T cellmediated antitumor immunity. DC vaccination strategies tested in glioma patients in phase I clinical trials demonstrated significant cytotoxic T cell and memory T-cell infiltration in areas of intracranial tumor (10, 11) . Efforts have also been made to enhance the potency and selectivity of antiglioma immune responses by adoptive immune therapy utilizing tumor-infiltrating lymphocytes (12) . A 50% reduction in tumor size was observed in 2 out of 5 patients who were administered cytotoxic T lymphocytes generated by treatment with IL2 and autologous glioma cells (13) . Clinical trials have also tested the potency of cytotoxic cells generated by stimulation with phytohaemagglutinin, anti-CD3 antibodies, and IL2 or through the stimulation of peripheral blood lymphocytes with IFNg, IL2, anti-CD3 antibodies, and IL1a (14, 15) . Our own data have shown that modulating the T-cell infiltration into the tumor microenvironment and enhancing T-cell effector functions through the overexpression of IFNg or IL2 or inhibition of NF-kB signaling extended the median survival of RG2 tumor-bearing rats as compared with Ad-Flt3L þ Ad-TK/GCV-treated group (16) . Overexpression of IFNg resulted in upregulation of MHC I expression on tumor cells potentially increasing tumor antigen presentation to T cells. Addition of Ad-IL-2 to the Ad-Flt3L þ Ad-TK/GCV immunotherapy enhanced the ratio of cytotoxic T lymphocytes/Tregs resulting in augmented antitumor CD8 þ T-cell responses. Similar effects were obtained by the inhibition of NF-kB signaling that resulted in reduced Foxp3 expression in CD4 þ T cells and enhanced IFNg release by CD8 þ T cells (17) .
An antitumor immune response that elicits tumor regression and long-term survival requires the recruitment and expansion of powerful antitumor cytotoxic T lymphocytes. In addition, generation of antitumor memory T-cell response is required for averting tumor relapse, and it has been suggested that memory CD8 þ T cells may determine the efficacy of antitumor therapies (18, 19) . An agent that has recently been shown to regulate the magnitude and quality of T-cell responses is rapamycin (20) . Rapamycin is a prototypic mTOR inhibitor that has been widely used clinically to prevent renal allograft rejection because of its immunosuppressive properties (21) . Rapamycin's ability to regulate Foxp3 expression, induce Treg differentiation and CD4 þ T cell anergy, is at least partially responsible for its tolerogenic effects (20, (22) (23) (24) . Rapamycin also inhibits type I interferon production by pDCs (25) . In contrast, several studies have highlighted the role of rapamycin as an immune-stimulatory agent. Rapamycin has been shown to enhance DC maturation and antigen presentation and promote the efficacy of autologous DC vaccination (26) . Rapamycin, through its effect on the mTOR signaling cascade, has also been shown to promote cytotoxic CD8 þ T-cell responses and induce immunologic memory in a T-cell intrinsic manner (19, 27, 28) . Also, memory T cells generated in the presence of rapamycin display improved protective capacity against infections. Indeed, rapamycin has been shown to potentiate the efficacy of vaccines targeting bacteria and viruses in mouse models (27, 29) . This prompted the question whether rapamycin and other mTOR inhibitors could be used to augment the efficacy of vaccines against tumors and in fact temsirolimus, another mTOR inhibitor has been shown to enhance the antitumor effects of heat shock protein cancer vaccines (30) .
Here, we tested the hypothesis that administration of rapamycin along with immune-mediated gene therapy would augment the cytotoxic and memory T-cell response against GBM. Using two GBM models in rats (RG2) and mice (GL26), we show that rapamycin enhances the cytotoxic activity of CD8 þ T cells. More importantly, it also promotes the development of CD8 þ memory T-cell response. Rapamycin administration for a short duration results in eliciting a vigorous long-lasting antiglioma memory response. Consequently, tumor-bearing animals treated with immunotherapy in the presence of rapamycin show better survival and respond more strongly to a second tumor challenge.
Materials and Methods

Syngeneic glioma models
All animal experiments were performed in accordance with protocols approved by the University Committee on Use and Care of Animals (UCUCA) at the University of Michigan. RG2 cells (20,000 in 3 mL DMEM) were stereotactically implanted in the right striatum of syngeneic Fisher rats (220-250 g; Harlan Laboratories Inc.) at the coordinates of 1.0 mm anterior and 3.2 mm lateral from the bregma and 6.0 mm ventral from the dura, as previously described (16, 31) . GL26 cells expressing ovalbumin were prepared as before (32) . Of note, 60,000 GL26-OVA cells in 1 mL DMEM were stereotactically implanted in the right striatum of syngeneic C57BL/6 mice (5-7 week; Harlan Laboratories Inc.) at the coordinates of 0.5 mm anterior and 2.1 mm lateral from the bregma and 3.2 mm ventral from the dura. Five days after tumor implantation, Fisher rats received an intratumoral injection of 3 mL of Ad vectors stereotactically using the same burr hole in four locations at 7.0 mm, 6.0 mm, 5.0 mm, and 4.0 mm ventral from the dura for the RG2 glioma model. C57BL/6 mice received 1.5 mL of Ad vectors in three locations at 3.8 mm, 3.5 mm, and 3.2 mm ventral from the dura at 14 days after tumor implantation. Animals were treated with 3 Â 10 8 pfu of Ad-Flt3L or 1 Â 10 8 pfu of Ad-TK or both Ad-Flt3L and Ad-TK. Animals treated with Ad-TK also received 25 mg/kg GCV twice daily for 7 days (mice) or 10 days (rats) starting the day after vector injection.
Rapamycin administration
Rapamycin (1.5 mg/kg; LC Laboratories) was administered intraperitoneally (i.p.) to the animals daily.
Quantification of DC maturation status
Antibodies for flow cytometry were obtained from BD Biosciences unless indicated otherwise. List of antibody clones used are indicated in Supplementary Table S1 . Flt3L-derived DCs (1 Â 10 6 ) were incubated for 48 hours in media only or in the presence of 50 ng/mL of LPS (Invitrogen) or 10 ng/mL rapamycin þ 50 ng/mL LPS. Forty-eight hours later, DC maturation markers CD80, CD86, MHC II, CD40, and CD25 were analyzed by flow cytometry. BMDCs were stained in FACS buffer (2% FBS in PBS) with anti-rat antibodies CD80, CD86, RT1B (MHC type II), CD40 (eBioscience), and CD25 for 30 minutes at 4 C. Data were acquired using a FACScan flow cytometer and analyzed with Summit software v4.3. Live cells (50,000) were recorded for each sample. Release of IL10, IFNg and IL12 from BMDC was determined in culture supernatant by ELISA (IL10 and IFNg, R&D Systems; IL12, Invitrogen). Absorbance was read on Spectramax Plus (Molecular Device) plate reader.
Antigen-specific effector and memory T-cell functions
Memory T cells in RG2 tumor-bearing rats were analyzed at day 33 after tumor implantation. Single-cell suspensions from spleen and dLNs were prepared as before followed by staining with CD3, CD8, CD45RC, and CD62L antibodies (7) . Memory responses were visualized by staining for CD45RC þ CD62L high cells among the CD3 þ CD8 þ T cells in the spleen. At least 50,000 live cells (determined by FSC/SSC) were acquired for each spleen and LN sample. For GL26-OVA model, 24 days or 89 days after tumor implantation or 5 days after the second tumor challenge at 90 days (day 95), brains, spleens, and dLNs were harvested from mice. Tumorinfiltrating immune cells were isolated as before (7) 
Statistical analysis
All statistical analysis was carried out using the GraphPad Prism software (version 5.0a). Kaplan-Meier survival curves were analyzed using the Mantel log-rank test. Costimulatory ligand expression and cytokine release from DCs was analyzed by one-way ANOVA followed by Bonferroni post-test. Antigen-specific cytotoxic and memory CD8 þ T-cell responses were analyzed using one-way ANOVA followed by Bonferroni post-test. P values of < 0.05 were considered to be significant.
Results
Rapamycin enhances therapeutic efficacy of Ad-Flt3L þ Ad-TK/GCV-mediated gene therapy in the RG2 intracranial glioma model Rapamycin and its analogs have exhibited clinical benefits against tumors such as endometrial and renal cancer either through a direct growth-inhibitory effect on cancer cells or through its ability to determine T-cell fate (33) . To test whether rapamycin could further enhance the antitumor immunity elicited by Ad-TK/GCV or Ad-TK/GCV þ Ad-Flt3L gene therapy, rats were implanted with RG2 tumors, and 5 days after tumor implantation, Ad-TK/ GCV alone or the combination Ad-Flt3L þ Ad-TK/GCV immune-mediated gene therapy was initiated. Rats were also treated with rapamycin beginning 5 days after tumor implantation until day 40 (Fig. 1A) . Administration of Ad-TK/GCV gene therapy to the tumor-bearing rats resulted in increase in their median survival period of 19.5 days (saline treated) to 32 days (P < 0.01, Fig. 1B ). The median survival time of the animals treated with the Ad-Flt3L þ Ad-TK/GCV immunotherapy was also significantly enhanced from 19.5 days (saline treated) to 36 days (P < 0.01, Fig. 1D ). In addition, combining rapamycin administration with Ad-Flt3L þ Ad-TK/GCV immunotherapy resulted in an additional increase in the median survival time of tumor-bearing rats to 47 days compared with 36 days for the Ad-Flt3L þ Ad-TK/GCV immunotherapy alone-treated group (P < 0.001, Fig. 1D ). In fact, approximately 89% AE 10% of the RG2 tumor-bearing rats treated with rapamycin and immunotherapy survived beyond day 42 by when all tumor-bearing rats treated with immunotherapy alone had perished (Fig. 1D) . Consistent with the increased survival, rats treated with Ad-Flt3L þ Ad-TK/GCV therapy or rapamycin in combination with Ad-Flt3L þ Ad-TK/GCV showed a drastic reduction in the tumor volume at day 12 as compared with the salinetreated group (P < 0.01, Fig. 1E ). The difference in tumor volume was even more apparent at day 33 when the average tumor volume for Ad-Flt3L þ Ad-TK/GCVtreated animals was 77.41 AE 26.01 mm 3 , whereas rats treated with rapamycin þ Ad-Flt3L þ Ad-TK/GCV showed an average tumor volume of 3.1 AE 0.58 mm 3 . In contrast, rapamycin administration during Ad-TK/GCV cytotoxic gene therapy failed to further increase the survival of Ad-TK/GCV-only-treated mice, suggesting that rapamycin potentially modulates the antitumor immunesurveillance mechanisms mediated by Flt3L immunotherapy (Fig. 1B ). Animals treated with rapamycin alone also showed a significant increase in their survival period (24 days) compared with saline-administered rats (19.5 days), indicating a direct effect of rapamycin on tumor growth (P < 0.01, Fig 
Rapamycin affects cell surface markers and cytokine profiles of Flt3L-induced DCs
Rapamycin has previously been shown to exert immunosuppressive effects on DCs, and bone marrow-derived DCs generated in its presence show reduced production of proinflammatory cytokines and impaired ability to induce allogeneic T cell responses (35, 36) . In contrast, several studies have shown that rapamycin promotes proinflammatory cytokine release by DCs and enhances . Fisher rats were implanted in the striatum with 20,000 RG2 cells and, 5 days later, they were treated with either Ad-TK or Ad-Flt3L þ Ad-TK followed by treatment with GCV. Rapamycin was administered i.p. daily between 5 and 40 days after tumor implantation. B, Kaplan-Meier survival curves of rats (n ¼ 5 animals per group) treated with saline or rapamycin or Ad-TK/ GCV (TK) or rapamycin þ Ad-TK/GCV (TK þ rapa). Survival curves were compared using the Mantel-Cox test; ÃÃ , P < 0.01. C, RG2 cells were seeded at 5,000 cells per well in 12-well plate and incubated overnight at 37 C. Cells were treated with a combination of rapamycin (0, 1, 10, or 100 nmol/L) and Ad-TK (MOI ¼ 0, 20, 200) and, 24 hours later, incubated with 25 mmol/L GCV for an additional 48 hours. Cells were trypsinized and cell viability was analyzed by flow cytometry using annexin V (FITC) and PI staining. Double-negative cells were considered to be viable. Representative flow plots for 10 nmol/L rapamycin in combination with 0, 20, or 200 MOI of Ad-TK treatment are shown. ÃÃÃ , P < 0.005. D, Kaplan-Meier survival curves of rats treated with saline or rapamycin or AdFlt3L þ Ad-TK/GCV (Flt3L/TK) or rapamycin þ Ad-Flt3L þ Ad-TK/GCV (Flt3L/TK þ rapa). Survival curves were compared using the Mantel-Cox test; ÃÃ , P < 0.01; ÃÃÃ , P < 0.005. n ¼ 5-8 animals per group. E, brains from RG2 tumor-implanted saline or Flt3L/TK or Flt3L/TK þ rapa-treated rats were processed for stereology to determine the tumor volume at days 3, 5, 9, 12, 19, 26, and 33 (n ¼ 3-5 animals per time point for each treatment group) after tumor implantation. Data were compared using the unpaired two-tailed Student t test. Mean AE SEM is indicated; Ã , P < 0.05.
their T-cell activation potential (37, 38) . The increase in therapeutic efficacy observed after rapamycin coadministration with Ad-Flt3L þ Ad-TK/GCV treatment of RG2 intracranial glioma suggested that rapamycin could enhance the Flt3L-mediated recruitment and activation of DCs and priming of the anti-GBM T-cell response. To examine the effect of rapamycin on DC activation, expression of costimulatory molecules, and cytokine release from rapamycin-treated Flt3L-derived bone marrowderived DCs was monitored in the presence of LPS. Generation of plasmacytoid DCs (pDC) and conventional DCs (cDC) in mouse bone marrow-derived DCs was monitored by staining for B220 and CD11c markers on the cells obtained 7 days after Flt3L stimulation (Supplementary Fig. S3 ). However, due to the lack of a definitive marker for rat pDCs, FSC/SSC profiles were used to identify total DCs. LPS stimulation upregulated the expression of CD86, CD80, and CD40 on DCs compared with the media-treated group (P < 0.001, Fig. 2A ). The expression levels of CD86, CD80, and CD40 were slightly enhanced in the presence of rapamycin by 1.5, 1.3, and 1.2-fold, respectively, compared with the LPS-treated group (P < 0.001 vs. LPS, Fig. 2A ). In contrast, rapamycin stimulation did not enhance LPS-induced CD25 and MHC II expression on DCs ( Fig. 2A) . Because cytokines produced by DCs are crucial for the polarization of CD4 þ T cells and the subsequent generation of CD8 þ T-cell mediated adaptive immunity, we next examined the effect of rapamycin on the proinflammatory (IFNg and IL12) and immunesuppressive (IL10) cytokine release by DCs. Whereas rapamycin þ LPS stimulation resulted in a marginal decrease in IFNg secretion (1.1 fold vs. LPS, P < 0.001), rapamycin þ LPS treatment boosted the levels of IL12 (1.2 fold vs. LPS, P < 0.001) and decreased IL10 release (2 fold vs. LPS, P < 0.001) by the DCs (Fig. 2B) . Overall, the presence of rapamycin during stimulation of DCs with LPS, therefore, strongly enhanced the T H 1/T H 2 cytokine ratio (P < 0.001, vs. LPS), indicating a bias toward immune-stimulatory cytokine release. These results prompted us to test whether rapamycin could also enhance the therapeutic efficacy of antiglioma DC vaccine. Animals vaccinated with DCs loaded with Ad-TK/ GCV-treated tumor cell lysate before tumor cell implantation ( Supplementary Fig. S4A ) exhibited increased circulating anti-RG2 antibodies ($4-fold increase in relative fluorescence vs. saline, P < 0.001, Supplementary Fig. S4B ) and increased cytotoxic activity against tumor cells (42.90% AE 1.25% target cell lysis) when compared with the saline-vaccinated controls (32.67% AE 0.24% target cell lysis, P < 0.01, Supplementary Fig. S4C ). However, DC vaccination failed to improve the survival of tumor-bearing rats (Supplementary Fig. S4D ). Interestingly and in agreement with the effect of rapamycin on DCs observed in vitro, animals immunized with the DC vaccine in the presence of rapamycin ( Supplementary Fig. S4E ) showed a significant increase in their median survival time (26 days vs. 21 days for saline, P < 0.001, Supplementary  Fig. S4F ).
Rapamycin enhances effector and memory CD8
þ Tcell function induced by Ad-Flt3L þ Ad-TK/GCV Because rapamycin promoted an increase in T H 1 cytokine release from DCs, which fosters the development of cytotoxic T lymphocyte-mediated immune response against pathogens and tumors, we examined the impact of rapamycin administration on T-cell activation in rapamycin þ Ad-Flt3L þ Ad-TK/GCV-treated, brain tumor-bearing rats. CD3 þ T cells from the dLNs of rapamycin þ Ad-Flt3L þ Ad-TK/GCV-treated tumor-bearing animals were harvested on day 12 and tested for their cytolytic activity toward RG2 cells (Fig. 3A) . At day 12, the tumor volumes in Ad-Flt3L þ Ad-TK/GCV only group are similar to the tumor volumes of rats treated with the combination therapy. Cytotoxicity of T cells isolated from animals treated with gene therapy in the presence of rapamycin was observed to be significantly higher (P < 0.05, 61.27% AE 1.5% target cell lysis at 20:1 E:T ratio) when compared with the gene therapy alone-treated group (51.07% AE 1.02% target cell lysis), indicating that rapamycin enhanced the cytotoxic activity of tumor-infiltrating T cells (Fig. 3B ). In addition, rapamycin elicited an increase in the percentage of central memory CD8
þ T cells in the spleen of tumor-bearing rats treated with Ad-TK/GCV þ Ad-Flt3L immunotherapy compared with the immunotherapy alone group (Fig. 3C ).
Rapamycin is required at an early stage to enhance therapeutic efficacy of Ad-Flt3LþAd-TK/GCV immunotherapy
The duration and timing of rapamycin administration has been shown to influence the development of CD8 þ T-cell memory response such that a short duration of high-dose rapamycin promoted CD8 þ T-cell persistence, whereas a prolonged high-dose regimen abolished memory responses (27, 39) . Therefore, to facilitate the development of a therapeutic regimen that effectively supports memory CD8 þ T-cell responses; we next characterized the impact of the timing of rapamycin administration in our system. We administered rapamycin to Ad-Flt3L þ Ad-TK/GCV-treated rats at two different time points after tumor implantation (Fig. 4A) . Interestingly, we observed that rapamycin could enhance the therapeutic efficacy of the Ad-Flt3L þ Ad-TK/GCV immunotherapy only when it was administered at the initiation of the treatment (Fig. 4B) . Rapamycin administration during the initiation of immunotherapy (between days 5 and 20 after tumor implantation) enhanced the survival of Ad-Flt3L þ Ad-TK/ GCV-treated rats from 35 to 60 days (P < 0.001, Fig.  4B ). In contrast, rapamycin administration after the initiation of immunotherapy (between days 20 and 40) failed to potentiate the efficacy of the immunogene therapy (P > 0.05 vs. Ad-Flt3L þ Ad-TK/GCV, Fig. 4C ). Previous data from our laboratory have shown that the generation of T-cell response following immunogene therapy peaks within 7 days after gene therapy administration. Our data, therefore, suggested that rapamycin mediates its effects by modulating TK/ Flt3L-mediated effector phase of the antitumor immune response and was crucially required during the expansion phase of the effector T cells.
Rapamycin enhances antigen-specific cytotoxic T-cell activity induced by Ad-Flt3L þ Ad-TK/GCV in a mouse syngeneic intracranial GBM model Our data with the RG2 glioma model indicated that rapamycin enhances the therapeutic efficacy of Ad-Flt3L þ Ad-TK/GCV immune-mediated gene therapy by modulating the generation of effector and memory T-cell responses. To examine the antigen specificity of the cytotoxic and memory T-cell response in more detail, we made use of the GL26 syngeneic glioma model in mice. GL26-OVA cells expressing the surrogate tumor antigen ovalbumin were implanted in the striatum of wild-type C57BL/6 mice and treatment was initiated as indicated (Fig. 5A) . The induction of antigen-specific cytotoxic CD8 þ T-cell responses and immunologic memory were visualized using the ovalbumin-derived peptide epitope SIINFEKL-H2K b tetramer. Flow cytometric analysis of tumor-infiltrating lymphocytes labeled with anti-CD8 antibodies and SIINFEKL-H2K b tetramers revealed more ovalbumin-specific CD8 þ T cells among the tumor-infiltrating cells in the Ad-Flt3L þ Ad-TK/GCV immunotherapy-treated mice (P < 0.001 vs. saline-treated group, Fig. 5B ). Although combining rapamycin with the immunogene therapy did not further increase the percentage of tetramer þ CD8 þ T cells in the brain, a significant increase in the frequency of CD8 þ T-producing IFNg was observed in these mice ($2-fold change vs. immunotherapy alone, P < 0.01) indicating an increase MHC II CD40 CD25 Figure 2 . Rapamycin (rapa) modulates the expression of costimulatory molecules and cytokine secretion from Flt3L-induced DCs. A, maturation markers on Flt3L-induced rat bone marrow DCs (gated using forward and side scatter profiles) were analyzed by flow cytometry after 7 days of culture (iDCs) or after stimulation with media (mock) or 50 ng/mL LPS or 50 ng/mL LPS þ 10 ng/mL rapamycin (LPS þ rapa) for 48 hours. Overlays from one representative experiment are depicted. Results in A are represented as fold change in mean fluorescence intensity (MFI). B, DCs harvested after 7 days in culture were treated with either 100 ng/mL rapamycin or saline (mock) in the presence or absence of LPS for 48 hours. Cytokine secretion was measured by ELISA. TH1/TH2 cytokine balance was estimated by IL12 vs. IL10 cytokine ratio. Data in A and B were analyzed using one-way ANOVA followed by Bonferroni post-test and are expressed as mean AE SEM; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.005; ns, not significant.
in the activity of CD8 þ T cells (Fig. 5C ). Consistent with our previous results, Ad-Flt3L þ Ad-TK/GCV immunotherapy induced ovalbumin-specific CD8 þ T cells in the dLNs (P < 0.05 vs. saline, Fig. 5E ). In addition, rapamycin treatment further enhanced the percentage of ovalbumin-specific central memory CD8 þ T cells in the spleen of tumor-bearing mice by approximately 1.3 fold (P < 0.05 vs. immunotherapy alone, Fig. 5D ). A similar trend was observed for cells from the dLNs (P > 0.05 vs. immunotherapy alone, Fig.  5E ). Consistent with the increased cytotoxic T-cell activity against tumor, rapamycin coadministration prolonged the survival of GL26-OVA tumor-implanted mice, such that 62% of mice treated with rapamycin þ Ad-Flt3L þ Ad-TK/GCV survived beyond day 60 compared with 41% from the immunotherapy treatment alone group (P < 0.05, Fig. 5F ). Rapamycin treatment alone failed to enhance the tumor-specific effector or memory T-cell responses and consequently provided no survival benefit.
Rapamycin enhances antigen-specific memory T-cell response against glioma
In most cases, GBM recurs after treatment (40); thus, development of immunologic memory response capable of recognizing brain tumor antigen, leading to the rejection of recurrent GBM becomes crucial for preventing relapse. Analysis of spleens and dLNs 10 days after tumor implantation showed that rapamycin administration induced higher percentage of antigen-specific memory CD8 þ T cells in the spleens of Ad-Flt3L þ Ad-TK/GCVtreated GL26-OVA tumor-bearing mice ($1.3 fold vs. immunotherapy alone, P < 0.05, Fig. 5D ). To determine the duration and robustness of the T cell-mediated 
for each group. Data were compared using the unpaired two-tailed Student t test. Mean AE SEM is indicated. memory response, mice that survived the first tumor were implanted with a second tumor in the contralateral hemisphere as indicated in the figure (Fig. 6A) . One day before the second tumor challenge (day 89), spleen and dLNs of these mice were examined for the presence of antigenspecific memory CD8 þ T cells. Mice treated with the combination of rapamycin þ Ad-Flt3L þ Ad-TK/GCV showed $1.5-fold higher percentages of antigen-specific CD44 high CD62L high tetramer þ CD8 þ T cells in the spleen and dLNs (P < 0.05 vs. immunotherapy alone, Fig. 6B and C). When rechallenged with tumor, mice also showed increased percentages of tetramer þ CD8 þ T cells in the brain ($1.3 fold, P < 0.001 vs. immunotherapy alone, Fig.  6D ). Furthermore, tumor-infiltrating CD8 þ T cells from rapamycin þ Ad-Flt3L þ Ad-TK/GCV-treated mice produced IFNg at a 3-fold higher frequency than those treated with immune gene therapy alone (P < 0.001, Fig. 6E ). Rapamycin administration in combination with Ad-Flt3L þ Ad-TK/GCV also conferred long-term survival advantage in response to the second tumor challenge; 100% of the mice in this treatment group survived beyond 90 days after the second tumor challenge compared with 60% of the mice from the immune gene therapy alone group (Fig. 6F) .
Discussion
Because of the limited success of the current treatment modalities for patients with GBM, there is an urgent need to develop novel therapies; particularly those that can inhibit tumor relapse. We have previously shown that immune-mediated gene therapy utilizing adenovirus-expressing Flt3L and TK followed by GCV administration exhibits effective antitumor immunity and results in tumor regression in several mouse and rat glioma models (4, 6, 41) . An important factor determining the success of these therapeutic approaches is the ability to harness the memory T-cell response. Recently, there has been considerable interest in the mTOR pathway as a determinant of T-cell fate. In particular, several studies have highlighted the use of the mTOR inhibitor rapamycin to modulate CD8 þ T-cell memory phenotype. Herein, we provide evidence that rapamycin potentiates the therapeutic efficacy of the immunemediated gene therapy in two syngeneic, intracranial glioma models, RG2 and GL26. We demonstrate that coadministration of rapamycin with Ad-Flt3L þ Ad-TK/GCV enhances the tumor antigen-specific cytotoxic CD8 þ T-cell responses. Furthermore, rapamycin strongly favors the generation of a robust memory CD8 þ T-cell response that, in turn, boosts the adaptive immune response against a second tumor challenge and confers a survival advantage to the mice.
Although rapamycin has traditionally been used as an immunosuppressive agent, reports have shown that it can enhance the effect of vaccines targeting bacterial and viral infections (27, 29) . We observed that rapamycin upregulated the LPS-induced expression of costimulatory ligands CD80 and CD86 on Flt3L-derived DCs. At the same time, rapamycin stimulation promoted the release 
) cells in spleen (D) and dLN (E) at day 24. Data in B-E were analyzed using one-way ANOVA, mean AE SEM are indicated; ÃÃ , P < 0.01; ÃÃÃ , P < 0.005, ns, not significant. F, Kaplan-Meier survival curves of mice bearing tumors treated with saline or rapamycin or Ad-Flt3L þ Ad-TK (Flt3L/TK) or Ad-Flt3L þ Ad-TK þ rapamycin (Flt3L/TK þ rapa). n ¼ 5 animals per group. Survival curves were compared using the MantelCox test; Ã , P < 0.05; ÃÃÃ , P < 0.005. Mean AE SEM is indicated; Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P < 0.005. F, survivors were rechallenged at day 90 without further treatment. Survival curves were compared using the Mantel-Cox test.
of T H 1-polarizing cytokines by LPS-stimulated DCs, indicating that rapamycin favors the development of the T H 1 phenotype. Consistent with the effect of rapamycin on DCs, we observed that administration of rapamycin at the time of DC vaccination prolonged the survival of RG2 tumor-bearing rats. In addition, rapamycin has been shown to enhance the life span of activated DCs, thus increasing the duration of their interaction with T cells. The shortened life span of activated DCs is one of the factors responsible for the modest success of DC vaccination in clinics and could be why DC vaccination alone failed to improve the survival of RG2 tumor-bearing rats in the absence of rapamycin in our system (26) . Apart from its effects on DC maturation and kinetics, rapamycin has been shown to influence CD4 þ T-cell fate and memory CD8 þ T-cell development (19, 20, 27, 42) . We thus tested whether rapamycin could enhance the therapeutic efficacy of the Flt3L/TK immunogene therapy, which relies on the recruitment of antigen-presenting cells to the tumor environment and priming of T-cell responses (5, 7). We observed that combining rapamycin administration with Ad-Flt3L þ Ad-TK/GCV gene therapy led to a remarkable increase in the survival of tumor-bearing animals in both RG2 (rat) and GL26 (mice) glioma models. Rapamycin by itself can induce apoptosis and, consistent with previous studies, it increased the sensitivity of RG2 cells to Ad-TK/GCV and showed a marginal increase in the survival of tumor-bearing animals as compared with the saline-treated group. However, rapamycin-induced tumor cell apoptosis does not appear to be the primary mechanism contributing to tumor regression as no significant difference in survival between Ad-TK/GCV and Ad-TK/GCV þ rapamycin-administered animals was observed. Instead, our data suggest that rapamycin mediates its effects by potentiating the TK/Flt3L-mediated antiglioma immune response. The observation that the effect of rapamycin is abolished if its administration is delayed would support the hypothesis that it is crucially required during the antigen presentation and the subsequent expansion phase of antitumor T cells. Accordingly, we observed enhanced cytotoxic T-cell responses as indicated by the increased lysis of RG2 tumor cells by activated T cells isolated from the dLNs of tumor-bearing animals. GL26-OVA tumor-implanted mice also showed elevated percentages of tumor-specific and IFNg-producing CD8 þ T cells. Of note, minimal contraction of antigenspecific CD8 þ T cells was observed at day 89 compared with the frequency of antigen-specific CD8 þ T cells at day 24 in the rapamycin-treated group. Because no significant differences in the percentage of antigen-specific CD8 þ T cells in the presence or absence of rapamycin were observed at day 24, it would suggest that rapamycin modulates the function and quality of T-cell responses rather than their proliferation. Our data are in accordance with the observations by Araki and colleagues who showed that rapamycin administration during the effector to memory transition phase was crucial to the generation of improved memory T-cell responses (27) . Thus, in our experiments, initiating rapamycin treatment after day 20 failed to affect the survival of tumor-bearing animals. Rapamycin treatment also accelerated memory T-cell development as indicated by the increased percentages of CD44 high CD62L high CD8 þ T cells. This would also imply the generation of a robust central memory response, as CD62L expression is high on central memory T cells. Memory T cells with high CD62L expression are also associated with enhanced proliferative capacity (43) . Of note, the effects of rapamycin administration were long lasting as higher numbers of memory T cells were observed at day 89 along with an increased frequency of tumor-specific IFNg þ CD8 þ T cells at day 95, even though the treatment with rapamycin was suspended at day 42. Indeed, this enhanced immunologic memory was associated with prolonged survival when the mice were challenged with a second tumor implantation. Taken together, our data demonstrate that rapamycin enhances the therapeutic efficacy of Ad-Flt3L þ Ad-TK/GCV gene therapy in a 2-fold manner: (i) by enhancing the functional quality of the antiglioma cytotoxic CD8 þ T-cell response and promoting the maintenance of tumor antigen-specific CD8 þ T cells, and (ii) eliciting a potent CD8 þ memory phenotype resulting in heightened antitumor effector CD8 þ T-cell response when rechallenged with the tumor. Moreover, we provide evidence that rapamycin administration for a short duration is sufficient to boost antitumor CD8
þ memory T-cell response that provides longterm survival advantage in the event of tumor rechallenge. Because relapse is a common occurrence in patients with GBM, our studies point to rapamycin administration as a novel therapeutic target to be used in combination with TK/Flt3L immune-gene therapy in a phase I clinical trial for GBM.
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